Market capitalization | $356.76m |
Enterprise Value | $141.08m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 1.61 |
Turnover (TTM) Turnover | $0.00 |
EBIT (operating result TTM) EBIT | $-85.74m |
Free cash flow (TTM) Free cash flow | $-66.05m |
Cash position | $223.85m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
11 Analysts have issued a Cabaletta Bio Inc forecast:
11 Analysts have issued a Cabaletta Bio Inc forecast:
Dec '23 | |
Current assets | 244 244 |
Fixed assets | 9.16 9.16 |
Total assets | 254 254 |
Dec '23 | |
Equity | 236 236 |
Debt capital | 17 17 |
Total capital | 254 254 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.
Head office | United States |
CEO | Steven Nichtberger |
Employees | 103 |
Founded | 2017 |
Website | www.cabalettabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.